Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1982 Aug;37(2):720–727. doi: 10.1128/iai.37.2.720-727.1982

Role of antiviral antibodies in resistance against coxsackievirus B3 infection: interaction between preexisting antibodies and an interferon inducer.

C T Cho, K K Feng, V P McCarthy, M F Lenahan
PMCID: PMC347590  PMID: 6288570

Abstract

An experimental model of coxsackievirus B3 infection in newborn mice was utilized to examine the protective role of antiviral antibodies and an interferon inducer, polyinosinic acid-polycytidylic acid [poly(I:C)]. Subcutaneous administration to the infected mice of specific antiviral antibodies resulted in significant protection against coxsackievirus B3 infection. Antibody-treated animals had shortened viremia, early clearance of virus from tissues, and a reduced mortality rate. Dose response to antibodies was clearly demonstrated. However, the time of antibody administration in relation to the infection cycle was important. The protection was observed if antibodies were given before infection (24 h) or shortly after (2 h) infection. Administration of antibodies 24 h after infection resulted in no protection. The interferon inducer poly(I:C) prolonged the survival time of the infected mice, but this protective effect was incomplete and could only be demonstrated in animals treated before infection (24 h) or shortly after (2 h) infection. Enhanced protection against lethal coxsackievirus B3 infection was achieved in animals treated with a combination of antiviral antibodies and poly(I:C). These data confirm that antibody-mediated immunity plays a significant role in resistance against coxsackievirus B3 infection and suggest that antiviral antibodies may interact with poly(I:C) or work independently to produce an enhanced protective effect.

Full text

PDF
720

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baer G. M., Shaddock J. H., Moore S. A., Yager P. A., Baron S. S., Levy H. B. Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine. J Infect Dis. 1977 Aug;136(2):286–291. doi: 10.1093/infdis/136.2.286. [DOI] [PubMed] [Google Scholar]
  2. Catalano L. W., Jr, Baron S. Protection against herpes virus and encephalomyocarditis virus encephalitis with a double-stranded RNA inducer of interferon. Proc Soc Exp Biol Med. 1970 Feb;133(2):684–687. doi: 10.3181/00379727-133-34544. [DOI] [PubMed] [Google Scholar]
  3. Cho C. T., Feng K. K., Brahmacupta N. Synergistic antiviral effects of adenine arabinoside and humoral antibodies in experimental encephalitis due to Herpesvirus hominis. J Infect Dis. 1976 Feb;133(2):157–167. doi: 10.1093/infdis/133.2.157. [DOI] [PubMed] [Google Scholar]
  4. Cho C. T., Feng K. K. Combined effects of acycloguanosine and humoral antibodies in experimental encephalitis due to Herpesvirus hominis. J Infect Dis. 1980 Sep;142(3):451–451. doi: 10.1093/infdis/142.3.451. [DOI] [PubMed] [Google Scholar]
  5. Cho C. T., Feng K. K. Interaction of adenine arabinoside and host defense factors in experimental infections due to Herpesvirus hominis. J Infect Dis. 1977 Mar;135(3):468–472. doi: 10.1093/infdis/135.3.468. [DOI] [PubMed] [Google Scholar]
  6. Cho C. T., Feng K. K. Synergistic effects of antiviral agents and humoral antibodies in experimental Herpesvirus hominis encephalitis. Ann N Y Acad Sci. 1977 Mar 4;284:321–334. doi: 10.1111/j.1749-6632.1977.tb21967.x. [DOI] [PubMed] [Google Scholar]
  7. Field A. K., Tytell A. A., Lampson G. P., Hilleman M. R. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc Natl Acad Sci U S A. 1967 Sep;58(3):1004–1010. doi: 10.1073/pnas.58.3.1004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. GRODUMS E. I., DEMPSTER G. Myocarditis in experimental Coxsackie B-3 infection. Can J Microbiol. 1959 Dec;5:605–615. doi: 10.1139/m59-074. [DOI] [PubMed] [Google Scholar]
  9. Galabov A. S., Velichkova E. H. Antiviral activity of N-phenyl-N'-aryl- or alkylthiourea derivatives in Coxsackie virus infections in mice. Antimicrob Agents Chemother. 1974 Jan;5(1):1–8. doi: 10.1128/aac.5.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harmon M. W., Janis B. Therapy of murine rabies after exposure: efficacy of polyriboinosinic-polyribocytidylic acid alone and in combination with three rabies vaccines. J Infect Dis. 1975 Sep;132(3):241–249. doi: 10.1093/infdis/132.3.241. [DOI] [PubMed] [Google Scholar]
  11. Lerner A. M., Wilson F. M. Virus myocardiopathy. Prog Med Virol. 1973;15:63–91. [PubMed] [Google Scholar]
  12. Lodmell D. L., Niwa A., Hayashi K., Notkins A. L. Prevention of cell-to-cell spread of herpes simplex virus by leukocytes. J Exp Med. 1973 Mar 1;137(3):706–720. doi: 10.1084/jem.137.3.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Modlin J. F., Polk B. F., Horton P., Etkind P., Crane E., Spiliotes A. Perinatal echovirus infection: risk of transmission during a community outbreak. N Engl J Med. 1981 Aug 13;305(7):368–371. doi: 10.1056/NEJM198108133050703. [DOI] [PubMed] [Google Scholar]
  14. Norris D., Loh P. C. Coxsackievirus myocarditis: prophylaxis and therapy with an interferon stimulator. Proc Soc Exp Biol Med. 1973 Jan;142(1):133–136. doi: 10.3181/00379727-142-36975. [DOI] [PubMed] [Google Scholar]
  15. Paque R. E., Gauntt C. J., Nealon T. J. Assessment of cell-mediated immunity against coxsackievirus B3-induced myocarditis in a primate model (Papio papio). Infect Immun. 1981 Jan;31(1):470–479. doi: 10.1128/iai.31.1.470-479.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Park J. H., Baron S. Herpetic keratoconjunctivitis: therapy with synthetic double-stranded RNA. Science. 1968 Nov 15;162(3855):811–813. doi: 10.1126/science.162.3855.811. [DOI] [PubMed] [Google Scholar]
  17. Rager-Zisman B., Allison A. C. Effects of immunosuppression on coxsackie B-3 virus infection in mice, and passive protection by circulating antibody. J Gen Virol. 1973 Jun;19(3):339–351. doi: 10.1099/0022-1317-19-3-339. [DOI] [PubMed] [Google Scholar]
  18. Rager-Zisman B., Bloom B. R. Immunological destruction of herpes simplex virus I infected cells. Nature. 1974 Oct 11;251(5475):542–543. doi: 10.1038/251542a0. [DOI] [PubMed] [Google Scholar]
  19. Reyes M. P., Lerner A. M. Interferon and neutralizing antibody in sera of exercised mice with coxsackievirus B-3 myocarditis. Proc Soc Exp Biol Med. 1976 Feb;151(2):333–338. doi: 10.3181/00379727-151-39204. [DOI] [PubMed] [Google Scholar]
  20. Shore S. L., Nahmias A. J., Starr S. E., Wood P. A., McFarlin D. E. Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus. Nature. 1974 Sep 27;251(5473):350–352. doi: 10.1038/251350a0. [DOI] [PubMed] [Google Scholar]
  21. TAMM I., EGGERS H. J. SPECIFIC INHIBITION OF REPLICATION OF ANIMAL VIRUSES. Science. 1963 Oct 4;142(3588):24–33. doi: 10.1126/science.142.3588.24. [DOI] [PubMed] [Google Scholar]
  22. Woodruff J. F., Woodruff J. J. Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J Immunol. 1974 Dec;113(6):1726–1734. [PubMed] [Google Scholar]
  23. Worthington M., Levy H., Rice J. Late therapy of an arbovirus encephalitis in mice with interferon and interferon stimulators. Proc Soc Exp Biol Med. 1973 Jul;143(3):638–643. doi: 10.3181/00379727-143-37382. [DOI] [PubMed] [Google Scholar]
  24. Yeager A. S., Arvin A. M., Urbani L. J., Kemp J. A., 3rd Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect Immun. 1980 Aug;29(2):532–538. doi: 10.1128/iai.29.2.532-538.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES